Subscribe

Neon Bloom, Inc. (NBCO)

USD0.01 +0.00 (+0.84%)
US OTC Healthcare Biotechnology
Address 99 Wall Street 10005
New York City, NY, US
CEO Greg Bauer
IPO 2007-09-21
CIK 1383637 ISIN US6405031088

Explore sections of this company profile

Description

Neon Bloom, Inc. functions as a principal investment firm, with a core focus on acquiring enterprises. Established in 2015, this New York-based company primarily directs its capital towards groundbreaking agricultural solutions and the related technological products and services that support them, operating on an international scale.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.01 +0.00 (+0.84%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
26.1K
Beta
0.56
Float Shares
194.69M
Free Float %
91.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% -0.06% +4.06% -17.47% +6.85% +10.46% -27.47% -94.85% -98.25% -99.93% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.01
Quality scores
Altman Z-Score
6.25
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
  • Revenue growth Biotechnology: +1.6%
    -85.7% Q4'25: -72.9% (vs Q3'24)
  • EPS growth Biotechnology: +29.7%
    +112.6% Q4'25: +226.9% (vs Q3'24)
  • FCF margin FCF growth · Biotechnology: +16.2%
    -10.9% Q4'25: +14.3% (vs Q3'24)
  • EBIT margin Biotechnology: +0.0%
    -10.5% Q4'25: +8.8% (vs Q3'24)
  • ROIC Biotechnology: -16.1%
    Q4'25: -28.3% (vs Q3'24)
  • Share dilution Biotechnology: -3.4%
    +74.6% Q4'25: 0.0% (vs Q3'24)
  • Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.69× Q4'25: 0.49× (vs Q3'24)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.56) × ERP
WACC = 82% × Ke + 18% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 0.01
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-22 C- 1/5 1/5 4/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
239.3K
OE per share TTM
0.00
Owner's Yield
15.70%
Maintenance CapEx ratio
Maint CapEx / Avg PPE
0.1%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
2
Beneficial owners (>5%)
# Reporting person Amount owned % of class Sole voting Shared voting Sole dispositive Shared dispositive Type Citizenship Filing date SEC filing
1 ID – Not applicable 687.0K 8.53% 687.0K 687.0K CO Virgin Islands 2010-01-12
2 ID. – Not applicable 56.0K 1.00% 687.0K 687.0K CO Virgin Islands 2008-10-22

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-242.9K
Shares Outstanding
212.26M

Executive compensation

Executive compensation (annual)
# Year Executive Salary Bonus Stock award Option award Incentive Other Total % Stock-
based
Filing
1 2008 Zahir Teja President, CEO, Director 160.0K 160.0K 0.00%
2 2008 Neev Nissenson VP, Secretary, Treasurer, CFO and Director 109.0K 109.0K 0.00%
3 2008 Teja N. Shariff Former CFO, Treasurer and CAO 60.0K 60.0K 0.00%
4 2007 Zahir Teja President, CEO, Director 120.0K 178.2K 298.2K 59.76%
5 2007 Neev Nissenson VP, Secretary, Treasurer, CFO and Director 50.0K 89.1K 139.1K 64.05%
6 2007 Neev Nissenson VP, Secretary, Director 50.0K 89.1K 139.1K 64.05%
7 2007 Teja N. Shariff CFO, Treasurer, CAO 40.0K 40.0K 0.00%
8 2007 Teja N. Shariff Former CFO, Treasurer and CAO 40.0K 40.0K 0.00%
9 2006 Zahir Teja President, CEO, Director 120.0K 120.0K 0.00%
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2009-06-22 DEF 14A
2008-07-07 DEF 14A

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2022-04-21 253G2
2022-04-15 253G1
2022-03-31 QUALIF
2022-03-30 CORRESP
2022-03-22 1-A/A
2022-03-17 UPLOAD
2022-03-04 CORRESP
2022-03-04 1-A/A
2022-02-01 UPLOAD
2022-01-05 1-A

Executive team

NameTitleCompensationGender
David Grand Secretary 23.6K male
Greg Bauer Chief Executive Officer & Director male
Daniel Levinson Associate male
Robyn Frick President female
Steven Salsburg Treasurer
Walter Tabaschek Chief Financial Officer & Chief Operating Officer male
Paul De Kleijn Chief Science Advisor male
ESG Rating
C
BIOTECHNOLOGY
2011
E (Environmental)
37.8 / 56.3
Company / Sector avg.
S (Social)
44.1 / 62.4
Company / Sector avg.
G (Governance)
48.0 / 60.9
Company / Sector avg.
ESG Total
43.3 / 59.9
Company / Sector avg.
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits